Dose-response : a publication of International Hormesis Society · 2026
Comparison of the Efficacy of Different Doses of Filgotinib in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on the RCTs.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ye Xia, Zhu Sidong, Wang Dongying, Hu Lifeng, Li Yudie, Wu Qingping, Chen Jingqi, Chen Bangsheng
Аннотация
OBJECTIVE: This study compared the efficacy of different doses of filgotinib (100 mg vs 200 mg) in the treatment of rheumatoid arthritis (RA).
METHODS: We conducted a systematic review of 4 electronic databases up to January 2025. Primary outcome measures included ACR20, ACR50, ACR70.
RESULTS: Five RCTs were included in this analysis, in which 2191 patients with RA were evaluated, 100 mg filgotinib was noninferior to 200 mg filgotinib in the efficacy of ACR20 (P = 0.33, RR = 0.96). However, 100 mg filgotinib was inferior to 200 mg filgotinib for RA when using ACR50 (P = 0.04, RR = 0.92) and ACR70 (P = 0.02, RR = 0.86) as outcome measures. At 24 weeks, 100 mg filgotinib was inferior to 200 mg filgotinib at ACR50 (P = 0.07, RR = 0.84), and there was no significant difference between 100 mg and 200 mg filgotinib at ACR70 (P = 0.54, RR =0.88). The 52-week results showed 100 mg filgotinib was inferior to 200 mg filgotinib at ACR70 (P = 0.01, RR = 0.86).
CONCLUSION: Reduced dose filgotinib (100 mg) may be used as a potential treatment option for RA when treatment is required.
METHODS: We conducted a systematic review of 4 electronic databases up to January 2025. Primary outcome measures included ACR20, ACR50, ACR70.
RESULTS: Five RCTs were included in this analysis, in which 2191 patients with RA were evaluated, 100 mg filgotinib was noninferior to 200 mg filgotinib in the efficacy of ACR20 (P = 0.33, RR = 0.96). However, 100 mg filgotinib was inferior to 200 mg filgotinib for RA when using ACR50 (P = 0.04, RR = 0.92) and ACR70 (P = 0.02, RR = 0.86) as outcome measures. At 24 weeks, 100 mg filgotinib was inferior to 200 mg filgotinib at ACR50 (P = 0.07, RR = 0.84), and there was no significant difference between 100 mg and 200 mg filgotinib at ACR70 (P = 0.54, RR =0.88). The 52-week results showed 100 mg filgotinib was inferior to 200 mg filgotinib at ACR70 (P = 0.01, RR = 0.86).
CONCLUSION: Reduced dose filgotinib (100 mg) may be used as a potential treatment option for RA when treatment is required.